Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellCept in High-Risk Penetrating Keratoplasty
DRKS00000011Phase 4Completed
- Sponsor
- Roche
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of mycophenolate mofetil in corneal degeneration, keratoplasty rejection (CGR), sponsored by Roche. Started Sep 2008; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
corneal degenerationkeratoplasty rejection (CGR)
Beyond the preview
Go deeper on DRKS00000011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000011.